THU0394 Rheumatologists use different cut offs for disease activity in real life – the experience with golimumab in ankylosing spondylitis – a subanalysis from the non-interventional go-nice trial

Abstract

BackgroundInternational recommendations for the management of axial spondyloarthritis including ankylosing spondylitis (AS) suggest a BASDAI level of disease activity of ≥4 to indicate treatment with biologics. Other cut-offs have rarely...